Microneedle Sensor Dermis Positioning for Low-Latency Glucose Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current subcutaneously-implanted analyte-selective sensors experience significant latency due to their location in the poorly vascularized subcutaneous adipose tissue, leading to delayed detection of glucose levels, which is particularly problematic in diabetes management where timely glucose monitoring is crucial.
Innovation Solution
The implementation of microneedle-based analyte-selective sensors positioned in the dermis or viable epidermis, where the high vascularization and reduced diffusion distance enable rapid analyte quantification, leveraging the proximity to the capillary plexus to minimize latency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If analyte-selective sensors are implanted in subcutaneous adipose tissue, then the sensors can be easily positioned and maintained, but significant latency occurs due to poor vascularization and long diffusion distance
Solution Approach 1:
The patent applies local quality by differentiating between subcutaneous adipose tissue (poorly vascularized, high latency) and dermal tissue (well-vascularized, low latency). The sensing element is specifically positioned in the dermis to exploit its superior vascularization and shorter diffusion distance to capillaries, while the rest of the sensor structure can remain in the more accessible subcutaneous layer for ease of positioning and maintenance.
2Ease of manufacture
If sensors are positioned deeper in subcutaneous tissue, then insertion is simpler and less painful, but the diffusion distance to analyte sources increases, worsening measurement latency
Solution Approach 1:
The sensor structure is designed with local quality differentiation: the sensing element is positioned shallowly in the dermis to minimize diffusion distance and latency, while the body of the sensor can extend deeper into subcutaneous tissue for easier insertion and anchoring. This creates a gradient of positioning depths optimized for different functional requirements.
Solution Approach 2:
The patent utilizes the vertical dimension of tissue depth to resolve the contradiction. By positioning the sensing element at a specific depth in the dermis rather than uniformly in subcutaneous tissue, it exploits the vertical gradient in vascularization and diffusion distance to achieve low latency while maintaining ease of insertion through the overlying skin layers.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly reduces sensor lag time by positioning the analyte-selective sensors within 500 micrometers of the dermal plexus, enabling faster detection of glucose levels and improving diabetes management by allowing for more timely interventions.
Implementation Method 1
the high vascularization and reduced diffusion distance enable rapid analyte quantification, leveraging the proximity to the capillary plexus to minimize latency
Data Source
AI summary
Devices and methods for low-latency analyte quantification enabled by the implementation of a microneedle-based analyte-selective sensor operating in the dermis or viable epidermis are disclosed herein. The sensing element of the device is contained within the microneedle-based analyte-selective sensor and configured to penetrate the stratum corneum of the skin and become positioned in the viable epidermis or dermis of the wearer such that the sensing element is located a spatial distance no greater than 500 micrometers from the plexus of the dermis of the wearer.